A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC

Study summary

The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of patients with advanced non-small cell lung cancer.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedDocetaxel and Ganetespib

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jul 1, 2016 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 3

Interventional

Where is it offered?267 U.S. locations

Locations may change over time.

Who runs it?Synta Pharmaceuticals Corp.

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 3
Sponsor: Synta Pharmaceuticals Corp.
Interventions being studied: Drug: Docetaxel; Drug: Ganetespib

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Disease setting

Metastatic or stage IV→

Treatment approach

Chemotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Advanced Stage IIIB or IV non-small-cell lung cancer (NSCLC)
Eastern Oncology Cooperative Group (ECOG) Performance Status 0 or 1
Prior therapy defined as 1 prior systemic therapy for advanced disease
Documented disease progression during or following most first line therapy for advanced disease
Adequate hematologic, hepatic, renal function

Reasons someone may not be able to joinExclusion criteria

Epidermal growth factor receptor (EGFR) mutations
Anaplastic lymphoma kinase (ALK) translocations
Predominantly squamous, adenosquamous or unclear histologic type
Active or untreated central nervous system (CNS) metastases
Active malignancies other than NSCLC within the last 5 years with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin
Serious cardiac illness or medical conditions
Pregnant or lactating women
Uncontrolled intercurrent illness

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Arizona Oncology Associates PC- NAHOAFlagstaff, Arizona
Arizona Oncology Associates, PC- NAHOAPrescott Valley, Arizona
Northern Arizona Hematology & Oncology AssociatesSedona, Arizona
Arizona Clinical Research Center, Inc.Tucson, Arizona
Pacific Cancer Medical Center, IncAnaheim, California
Comprehensive Blood & Cancer CenterBakersfield, California
City of Hope Comprehensive Breast Cancer CenterDuarte, California
UC San Diego Moores Cancer CenterLa Jolla, California
Loma Linda University Cancer CenterLoma Linda, California
VA Greater Los Angeles Healthcare SystemLos Angeles, California
Ronald Reagan UCLA Medical CenterLos Angeles, California
St. Joseph Hospital, Center for Cancer Prevention and TreatmentOrange, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 1, 2016. Always confirm current availability with the study team.

View original record ↗